Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

What's encouraging, however, is that there may be more benefits with GLP-1 drugs than simply losing weight and controlling ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area ...

Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...

In a separate development, Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.

Strive Compounding Pharmacy alleged in its lawsuit that Eli Lilly and Novo Nordisk have worked to lock telehealth providers ...